Allogene Stock Jumps As Off‑The‑Shelf CAR‑T Wipes Out Residual Lymphoma In Early Readout Allogene Therapeutics (NASDAQ: ALLO) is up more than 50%, trading sharply higher after early data showed its off‑the‑shelf CAR‑T candidate cema‑cel eli

Allogene Therapeutics (NASDAQ: $ALLO) is climbing after an early look at the ALPHA3 trial showed its donor‑derived CAR‑T cema‑cel rendered 58% of MRD‑positive B‑cell lymphoma patients MRD‑negative, versus 16% in the observation arm.
#AllogeneTherapeutics
prismmarketview.com/allogene-sto...

Allogene Therapeutics Upside Targets Top 180% Analysts cited by Yahoo Finance on Apr 12, 2026 see 180%+ upside for Allogene Therapeutics (ALLO); catalyst timing and financing are decisive for realization.

Allogene Therapeutics Upside Targets Top 180%: Analysts cited by Yahoo Finance on Apr 12, 2026 see 180%+ upside for Allogene Therapeutics (ALLO); catalyst timing and financing are decisive for… 👈 Read full analysis #AllogeneTherapeutics #Investing #StockMarket #AnalystRatings #HealthcareInvestment